Targeted therapy plus radiation for egfr-mutated lung cancer
Treatments studied
Part of Cancer, Lungs & breathing clinical trials.
This trial tests a combination of a targeted pill (befotertinib) and radiation for people with stage IV non-small cell lung cancer that has an EGFR mutation and has spread to only a few spots. The study uses a blood test to guide treatment and aims to see if this combination can help control the cancer better.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are aged 18 to 75.
- You have stage IV non-small cell lung cancer (NSCLC) with a limited number of metastases (up to 5 spots in up to 3 organs).
- Your cancer has an EGFR mutation (19Del or L858R).
- You have not had prior treatment for advanced lung cancer (except maybe adjuvant therapy if it was more than 6 months ago).
- You are generally in good health (able to care for yourself) and have adequate organ function.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests a new targeted pill (befotertinib) combined with chemotherapy for people with advanced EGFR-mutated non-small cell lung cancer. The treatment is adjusted based on how well the cancer responds, using a special blood test (MRD) to guide decisions.
This trial tests a combination of chemotherapy and a targeted drug (befotertinib) for people with non-small cell lung cancer whose cancer has stopped responding to a common type of targeted therapy. It aims to see if this new sequence can help overcome resistance.
This trial tests a new targeted pill (befotertinib) given before surgery, either with another targeted drug (bevacizumab) or with standard chemotherapy. The goal is to shrink the tumor and improve outcomes for people with a specific type of lung cancer.
This trial tests a targeted therapy (firmonertinib) combined with standard chemotherapy before surgery, to see if it can shrink tumors and improve outcomes for people with early-stage lung cancer that has a specific EGFR gene change.
This trial tests a drug called Befotertinib for people with non-small cell lung cancer that has uncommon EGFR mutations (like G719X, L861Q, S768I, or exon 20 insertions). It is for those who haven't taken an EGFR-targeted pill before and have had a previous chemotherapy stopped working or caused side effects.
This trial tests a combination of two targeted medicines (befotertinib and bevacizumab) before surgery for people with EGFR-mutant non-small cell lung cancer that cannot be removed right away. The goal is to see if this treatment can shrink the tumor and improve surgery outcomes.
Hear when a new Patients With Advanced Oligometastatic Non-small Cell Lung Cancer (NSCLC) Who Have Tested Positive for EGFR Mutations Confirmed by Histopathological Examination trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.